C4 Therapeutics Shares Rocket as Bristol Myers Squibb’s Mezigdomide Phase 3 Triumph Lights Up Protein Degrader Sector

C4 Therapeutics stock jumped after Bristol Myers Squibb announced strong Phase 3 SUCCESSOR-2 results for mezigdomide in multiple myeloma.